1340 related articles for article (PubMed ID: 7835801)
1. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
2. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
3. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
5. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
12. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
[TBL] [Abstract][Full Text] [Related]
13. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
[TBL] [Abstract][Full Text] [Related]
14. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
[TBL] [Abstract][Full Text] [Related]
15. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
[TBL] [Abstract][Full Text] [Related]
16. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
